Impact of disease-modifying therapies on MRI outcomes in patients with relapsing -remitting multiple sclerosis: A systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Impact of disease-modifying therapies on MRI outcomes in patients with relapsing -remitting multiple sclerosis: A systematic review and network meta-analysis

Published:2022-05 Issue: Volume:61 Page:103760
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Bose Debdipta,Ravi Renju^ORCID,Maurya Miteshkumar,Pushparajan Libby,Konwar Mahanjit^ORCID

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference49 articles.

1. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study;Arnold;J. Neurol.,2014

2. A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year;Bastianello;Can J Neurol. Sci. J. Can. Sci. Neurol.,1994

3. A comparative placebo-controlled clinical trial of the efficacy and safety of glatiramer acetate 20mg in patients with remitting multiple sclerosis: first-year study results;Boiko;Neurosci. Behav. Physiol.,2018

4. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis;Calabrese;Mult. Scler. J,2012

5. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial;Calabresi;Lancet Neurol.,2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments;Journal of Central Nervous System Disease;2024-09-13

2. Pattern of disease-modifying therapies use and related adverse events among multiple sclerosis patients;Brazilian Journal of Pharmaceutical Sciences;2024

3. Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis;CNS Drugs;2023-05